Skip to content
value.today

Fountain Therapeutics, Inc.

🇺🇸 Stanford, California, USABiotechnologyFounded 2018
Total raised
$27 M
3 rounds on record
Latest round
$16 M
Nov 2021
First round on record
May 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Fountain Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$16 MNo. 3$10 to $50 million

Fountain Therapeutics, Inc.: Raise no. 3, Nov 2021

Investors in this round

8 investors had bought by the notice of Dec 1, 2021: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Rando · Executive Officer, Director
  • William Greene · Executive Officer, Director
  • Alex Morgan · Director
  • Ashish Khanna · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Greene, Chief Executive Officer. Newest notice filed Dec 1, 2021. Read the notice at the SEC.

equitySEC
Feb 2020$6 MNo. 2$2 to $10 million

Fountain Therapeutics, Inc.: Raise no. 2, Feb 2020

Investors in this round

2 investors had bought by the notice of Feb 19, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Dimos · Executive Officer, Director
  • Thomas Rando · Executive Officer, Director
  • Ashish Khanna · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Dimos, Chief Executive Officer. Newest notice filed Feb 19, 2020. Read the notice at the SEC.

equitySEC
May 2018$5 MNo. 1$2 to $10 million

Fountain Therapeutics, Inc.: Raise no. 1, May 2018

Investors in this round

2 investors had bought by the notice of Sep 18, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas A. Rando · Executive Officer, Director, Promoter · Mr. Rando is the President, Treasurer, Secretary of the Issuer.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas A. Rando, President of the Issuer. Newest notice filed Sep 18, 2018 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Fountain Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2021).

    SEC Form D · Dec 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2021

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Fountain Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Fountain Therapeutics, Inc.
NameRoleNamed in
Thomas RandoExecutive officerDec 2021
William GreeneExecutive officerDec 2021
John DimosExecutive officerFeb 2020
Thomas A. RandoMr. Rando is the President, Treasurer, Secretary of the Issuer.Sep 2018
Alex MorganDirectorDec 2021
Ashish KhannaDirectorDec 2021
Thomas RandoDirectorDec 2021
William GreeneDirectorDec 2021
John DimosDirectorFeb 2020
Thomas A. RandoMr. Rando is the President, Treasurer, Secretary of the Issuer.Sep 2018
Thomas A. RandoMr. Rando is the President, Treasurer, Secretary of the Issuer.Sep 2018